XERS Q2 2021 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+339.4% YoY

Gross Profit

$6M62.0% margin

Operating Income

-$26M-289.5% margin

Net Income

-$28M-308.9% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+8.7%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$151M

Total Liabilities

$132M

Stockholders' Equity

$20M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$2M	+339.4%
Gross Profit	$6M	$728,000	+658.7%
Operating Income	-$26M	-$22M	-16.1%
Net Income	-$28M	-$24M	-14.2%